This is a retrospective/prospective, cohort, non-interventional observational study. Thismeans that all patients with documented COVID and HM diagnosed between February 2020 andstudy initiation will compose the retrospective part, while those diagnosed after studyapproval will enter prospective part.The total duration of the study will be 12 months.The study population will must be older than 18 years of age with HM and SARS-CoV-2infection. All patients with documented SARS-CoV-2 infection (COVID) and history oractive hematological malignancies, who refer to any Hematological Unit will be included.

This study is being conducted to study the use and application of a point-of-care (POC)Covid-19 test developed by Spartan BioSciences and recently approved for clinical use byHealth Canada. Phase I of this study will determine the best route for the swabs (nasal,throat, or both), and to determine if this POC test results are comparable to thestandard core-lab test results.

RACONA is a prospective trial that will test the hypothesis that nafamostat can lowerlung function deterioration and need for intensive care admission in COVID-19 patients.Design: Adult hospitalized COVID-19 patients will be randomized in a prospectivedouble-blind randomized placebo-controlled study to test the clinical efficacy ofnafamostat mesylate (administered intravenously) on top of best standard of care.Primary outcome measures: the time-to-clinical improvement, defined as the time fromrandomization to an improvement of two points (from the status at randomization) on aseven category ordinal scale or live discharge from the hospital, whichever comes first.

Acute kidney injury (AKI) has been identified as an independent risk factor forin-hospital mortality. The present study aims to investigate the incidence of AKI andrenal recovery of inpatients diagnosed with COVID-19.

Since the outbreak of a syndrome of acute respiratory distress associated to a novelcoronavirus 2 (SARS-Cov2) that began in China, Europe and France have to face a sanitaryemergency with critically care support when the patient evolves to an acute respiratorydistress (ARDS). In the context of supply shortages (ventilators, bed capacities) thatcountries have to deal with, data were lacking of characteristics and outcomes ofpatients admitted to intensive care unit (ICU). the purpose of this project is to reportthe epidemiology and the outcomes of a French cohort of critically ill patients withSARS-Cov2

In this study we will collect granular information on cancer patients infected withCOVID-19, as rapidly as possible. The mechanism for collection of this information is ade-identified centralized registry housed at Vanderbilt University Medical Center, withdata donations from internal and external health care professionals.

CORIA is an observational cohort study of immunosuppressed populations who test positivefor COVID-19. This includes people living with HIV, cancer, acquired immunodeficiencyassociated with other immunosuppressive therapy, primary immunodeficiency and recipientsof a solid organ transplant. Participants will have routine clinical data collected withoptional baseline collection and storage of a blood sample for storage . The study willbe conducted in up to 30 sites within Australia.

The primary objective of this research study is to assess Radiation Oncology healthcareproviders (i.e. faculty, residents and advanced practice providers (APPs) implementationand perception of telehealth for on treatment patients in lieu of in person on treatmentvisits during standard of care radiotherapy during COVID-19.

The study investigators are interested in learning more about how drugs, that are givento children by their health care provider, act in the bodies of children and young adultsin hopes to find the most safe and effective dose for children. The primary objective ofthis study is to evaluate the PK of understudied drugs currently being administered tochildren per SOC as prescribed by their treating provider.

Efficacy of Ivermectin in larger doses in COVID-19 treatment